Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 1/20 | 0.39 |
| ▸ | ABAT | P80404 | 2/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A12 | P48065 | 3/20 | 0.31 |
| ▸ | SLC6A11 | P48066 | 3/20 | 0.31 |
| ▸ | SLC6A13 | Q9NSD5 | 3/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | OAT | P04181 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | ANPEP | P15144 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27835423 | 1.00 | GABRR1 (0.39) | GABRR1ABATSLC6A4SLC6A12SLC6A11 | |
| SCHEMBL21178530 | 1.00 | GABRR1 (0.39) | GABRR1ABATSLC6A4SLC6A12SLC6A11 | |
| SCHEMBL19815798 | 0.84 | GABRR1 (0.36) | GABRR1SLC6A12SLC6A11SLC6A13MMP2 | |
| SCHEMBL30779755 | 0.84 | CYP2C19 (0.36) | GABRR1SLC6A4CYP1A2ALOX15CYP2C19 | |
| SCHEMBL1769221 | 0.79 | CYP2C19 (0.39) | GABRR1KDM4EALDH1A1CYP1A2ALOX15 | |
| SCHEMBL1907444 | 0.79 | — | — | |
| Hydrochloric Acid SCHEMBL18669317 | 0.77 | — | — | |
| SCHEMBL25283263 | 0.77 | ATM (0.34) | GABRR1MMP2ANPEP | |
| SCHEMBL18957397 | 0.77 | ATM (0.34) | GABRR1MMP2ANPEP | |
| SCHEMBL22413321 | 0.77 | ATM (0.34) | GABRR1MMP2ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11311542-B2 | Inhibitors of cyclin dependent kinase 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20210379065-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2021-12-09 | — | — | US | disclosed |
| EP-3740207-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | Syros Pharmaceuticals, Inc. (US) | 2020-11-25 | — | — | EP | disclosed |
| WO-2019143719-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2019-07-25 | — | — | WO | disclosed |
| EP-2297114-B1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2018-06-06 | — | — | EP | disclosed |
| US-20160046601-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2016-02-18 | — | — | US | disclosed |
| US-9221836-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-29 | — | — | US | disclosed |
| US-20150191486-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-07-09 | — | — | US | disclosed |
| EP-2202228-B1 | AMIDE COMPOUNDS AND USE OF THE SAME | TAKEDA PHARMACEUTICAL (JP) | 2014-12-10 | — | — | EP | disclosed |
| US-8664380-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-04 | — | — | US | disclosed |
| US-8329691-B2 | Amide compounds and use of the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-12-11 | — | — | US | disclosed |
| US-20100324010-A1 | AMIDE COMPOUNDS AND USE OF THE SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-23 | — | — | US | disclosed |
| EP-2202228-A1 | AMIDE COMPOUNDS AND USE OF THE SAME | Takeda Pharmaceutical Company Limited (JP) | 2010-06-30 | — | — | EP | disclosed |
| US-20100137587-A1 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324010-A1 | AMIDE COMPOUNDS AND USE OF THE SAME | REN, ACE, AGT | GABRR1 3322/4885ABAT 505/4885SLC6A4 1440/4885 |
| US-11311542-B2 | Inhibitors of cyclin dependent kinase 7 (CDK7) | CDK7, CDK3, CCNK | GABRR1 4683/4885ABAT 2229/4885SLC6A4 4076/4885 |
| US-20210379065-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CCNK | GABRR1 4683/4885ABAT 2229/4885SLC6A4 4076/4885 |
| US-20150191486-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | REN, AGT, ACE | GABRR1 1912/4885ABAT 879/4885SLC6A4 1776/4885 |
| US-20160046601-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | REN, AGT, ACE | GABRR1 1912/4885ABAT 879/4885SLC6A4 1776/4885 |
| US-20100137587-A1 | Heterocyclic compound and use thereof | REN, AGT, ACE | GABRR1 1912/4885ABAT 879/4885SLC6A4 1776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.